with HKL 24 or XDS 25 . Crystals belong to space group P2 1 2 1 2 1 with unit cell dimensions a ¼ 56.7 Å , b ¼ 67.7 Å and c ¼ 135.6 Å , and contain three molecules per asymmetric unit. . The refined model has excellent stereochemical quality and a free R-factor of 25.2%. A difference Fourier for the peptide-soaked crystal was calculated with phases from the CID model and identified strong density for the CTD peptide bound to one CID molecule (chain B). The two other CID molecules pack against each other, burying their peptide-binding sites. After peptide building, the CID-CTD model was refined to a free R-factor of 25.7%. Peptide binding does not result in significant conformational changes in the CID domain. Soaking experiments with phosphoserine did not reveal any additional electron density.
Transforming growth factor-b (TGF-b) potently inhibits cell cycle progression at the G1 phase 1, 2 . Smad3 has a key function in mediating the TGF-b growth-inhibitory response. Here we show that Smad3 is a major physiological substrate of the G1 cyclin-dependent kinases CDK4 and CDK2. Except for the retinoblastoma protein family 3, 4 , Smad3 is the only CDK4 substrate demonstrated so far. We have mapped CDK4 and CDK2 phosphorylation sites to Thr 8, Thr 178 and Ser 212 in Smad3. Mutation of the CDK phosphorylation sites increases Smad3 transcriptional activity, leading to higher expression of the CDK inhibitor p15. Mutation of the CDK phosphorylation sites of Smad3 also increases its ability to downregulate the expression of c-myc. Using Smad3 2/2 mouse embryonic fibroblasts and other epithelial cell lines, we further show that Smad3 inhibits cell cycle progression from G1 to S phase and that mutation of the CDK phosphorylation sites in Smad3 increases this ability. Taken together, these findings indicate that CDK phosphorylation of Smad3 inhibits its transcriptional activity and antiproliferative function. Because cancer cells often contain high levels of CDK activity 5, 6 , diminishing Smad3 activity by CDK phosphorylation may contribute to tumorigenesis and TGF-b resistance in cancers.
Cell cycle progression from G1 to S phase is governed by CDK4 and the homologous CDK6 as well as CDK2 (ref. 4 ). CDK4 and CDK6 are activated by D-type cyclins at early to mid-G1 phase, whereas CDK2 is activated by E-and A-type cyclins during late G1 and S phase, respectively 4 . The activities of CDK4 and CDK6, and of CDK2, are constrained by the p16 INK4 family and the p21 Cip/Kip family inhibitors, respectively 4 . TGF-b potently inhibits cell proliferation by causing cell cycle arrest at the G1 phase 1,2 . Smad proteins can mediate TGF-b growth inhibitory responses 1,2 . In the basal state, Smad2 and Smad3 are distributed throughout cells. In response to TGF-b, Smad2 and Smad3 are phosphorylated at the carboxyl terminus by TGF-b receptor and form complexes with Smad4 (refs 1, 2). These complexes then accumulate in the nucleus and regulate the transcription of target genes that include cell cycle regulators 1,2 , such as the CDK inhibitors p15 and p21 and the protooncogene c-myc (refs 7-16 Smad3 has a key function in responsiveness to TGF-b.
Because Smads contain potential CDK phosphorylation sites, we analysed whether they are substrates for CDKs. To investigate whether cyclin D-CDK4 can phosphorylate Smads, we performed an in vitro kinase assay with endogenous CDK4 immunoprecipitated from Mv1Lu mink lung epithelial cells by an affinity-purified CDK4-specific antibody. Full-length Smad proteins fused to glutathione S-transferase (GST) were used as substrates. Two frequently used fusion proteins of retinoblastoma protein (Rb) with GST were included as positive controls. As shown in Fig. 1a , the highly homologous Smad2 and Smad3 were phosphorylated. Smad4, which is homologous to Smad2 and Smad3 in the amino-terminal and C-terminal domains but divergent from Smad2 and Smad3 in the middle proline-rich region, was not phosphorylated (Fig. 1a) , nor was GST alone (data not shown). The phosphorylation was specific, because preincubation of the antibody with the CDK4 antigen peptide before immunoprecipitation significantly inhibited phosphorylation (Fig. 1a) . Because CDK4 has a very strict substrate specificity, indicated by its inability to phosphorylate the canonical CDK substrate histone H1 (ref. 4) , we further verified that CDK4 can indeed phosphorylate Smads by using bacterially expressed and in vitro reconstituted CDK4 (Fig. 1b) . Notably, Smad3 was phosphorylated to a greater extent than Rb by immunoprecipitated CDK4 from Mv1Lu cells (Fig. 1a) and many other cell lines (data not shown) as well as by reconstituted CDK4 (Fig. 1b) . Further substrate titration experiments comparing Smad3 and Rb phosphorylation by using either immunoprecipitated CDK4 or reconstituted CDK4 confirmed that Smad3 is an excellent substrate for CDK4 ( Supplementary Fig. S1 and Supplementary Table S1 ). Similar experiments indicated that Smad3 and Smad2, but not Smad4, can also be specifically phosphorylated by immunoprecipitated CDK2 (Fig. 1c) and bacterially expressed and in vitro reconstituted cyclin E-CDK2 or cyclin A-CDK2 complexes (Fig. 1d) .
To determine whether endogenous Smad3 is phosphorylated by G1 CDKs, we synchronized Mv1Lu cells at the G0/G1 phase by contact inhibition as described previously 23 . Cells were then released from growth arrest by plating into fresh medium and, at different time points, were labelled with 32 P-orthophosphate and immunoprecipitated by a Smad3-specific antibody to analyse the endogenous Smad3 phosphorylation status. Unlabelled cells prepared in parallel were analysed by flow cytometry to determine the cell cycle distribution at each time point. As shown in Fig. 2a, Smad3 phosphorylation oscillated in a cell-cycle-dependent manner. The maximal phosphorylation of Smad3 occurred at the G1/S Figure 2 Smad3 is phosphorylated by endogenous G1 CDKs in vivo. a, Endogenous Smad3 is phosphorylated in a cell cycle-dependent manner. Mv1Lu cells were synchronized by contact inhibition, then plated into fresh medium, labelled with 32 P-orthophosphate, immunoprecipitated (IP) first with a Smad3 antibody and subsequently with an anti-Rb antibody. The ERK activity profile, analysed by a phosphotyrosine antibody that recognizes only activated ERK (pERK1 and pERK2) in unlabelled lysates, indicates that ERK might contribute to Smad3 phosphorylation at very early, but not at the peak, phosphorylation time points. b, Schematic diagram of Smad3 structure. c, Mutation of the Thr 8 and four phosphorylation sites in the Smad3 linker region markedly decreases CDK4 and CDK2 phosphorylation in vitro. WT, wild-type. d, Left, p16 or p21 transfected into Mv1Lu/L17 cells can inhibit endogenous CDK to phosphorylate Smad3. Middle and right, cyclins transfected into COS cells can activate endogenous CDKs to phosphorylate Smad3, and p16 and p21 can inhibit this activity.
junction, indicating that Smad3 was phosphorylated by G1 CDKs. Subsequent immunoprecipitation of the 32 P-labelled cell lysates with an antibody against Rb showed that the peak of Rb phosphorylation slightly lagged behind that of Smad3 phosphorylation (Fig. 2a) , suggesting that Smad3 is a good substrate for CDK4 in vivo.
Smad3 contains nine potential CDK phosphorylation sites, four of which are located in the proline-rich linker region: Thr 178, Ser 203, Ser 207 and Ser 212 (Fig. 2b and Supplementary Fig. S2 ). The threonine at amino acid position 8 is potentially a good site, particularly for CDK4 (ref. 24) . Through a number of mutational studies, we found that simultaneous mutation of Thr 8 and the four sites in the linker, designated Smad3 (T8V/Linker Mut), markedly decreased phosphorylation by CDK4 or CDK2 (Fig. 2c) , indicating that CDK4 and CDK2 phosphorylation might occur within these five sites in vitro.
In transient transfection assays, Flag-Smad3 was phosphorylated, and p16 and p21 each inhibited the phosphorylation (Fig. 2d, left  panel) . Smad3 (T8V/Linker Mut) was phosphorylated to a much lower level than the wild-type Smad3. To determine whether the introduction of exogenous cyclins can activate endogenous CDK to phosphorylate Smad3, the wild-type or mutant version of Flag-Smad3 was cotransfected either individually or together with cyclins D, E or A. As shown in Fig. 2d (middle panel) , the phosphorylation of wild-type Flag-Smad3 was significantly increased by cotransfected cyclins. The effects of cyclins D or E can be inhibited by cotransfected p16 or p21, respectively (Fig. 2d,  right panel) . In contrast, phosphorylation of Smad3 (T8V/Linker Mut) was only slightly increased by cyclins D or E. These observations provide additional evidence that Smad3 is phosphorylated by CDK4 and CDK2 in vivo and that the phosphorylation occurs within these five sites.
To determine the exact CDK phosphorylation sites in Smad3, we generated phosphopeptide antibodies against each of the five potential phosphorylation sites: Thr 8 and the four sites in the linker (Thr 178, Ser 203, Ser 207 and Ser 212). Each of the five sites was phosphorylated by both CDK4 and CDK2 in vitro, and only Thr 8, Thr 178 and Ser 212 were phosphorylated by CDK4 and CDK2 in vivo (Supplementary Figures S3-S5 ). To confirm that the other four potential sites (Thr 131, Ser 316, Ser 391 and Ser 415) cannot be phosphorylated by CDK, we also generated phosphopeptide antibodies against each of these sites and found that these four sites indeed cannot be phosphorylated by CDK4 or CDK2 (data not shown). Mitogen-activated protein (MAP) kinase was shown to phosphorylate Smad3 in the linker region 25 . We found that Ser 203 and Ser 207 were phosphorylated by MAP kinase and that Thr 178 was phosphorylated mostly by CDK and to a lesser extent by MAP kinase (Supplementary Fig. S5 ).
To analyse the role of CDK phosphorylation of Smad3, we examined the effect of mutation of the Smad3 CDK phosphorylation sites on the p15 reporter gene. As shown in Fig. 3a , each of T8V, T178V and S212A has a higher activity than the wild-type Smad3 to stimulate the p15 promoter, and the triple mutant (T8V/ T178V/S212A) has the highest activity. Moreover, the GAL4-Smad3 triple mutant (T8V/T178V/S212A) has a higher activity than the wild-type GAL4-Smad3 on a GAL4-luciferase reporter gene in the absence as well as in the presence of different concentrations of TGF-b (Fig. 3b) . We also found that cotransfection of CDK4 RNA-mediated interference (RNAi) or CDK2 RNAi constructs increases the basal and TGF-b-induced p15 reporter gene activity (Fig. 3c) . Taken together, these results indicate that CDK phosphorylation of Smad3 can inhibit its transcriptional activity.
Smad3 also plays a critical role in the downregulation of c-myc expression by TGF-b (refs 13-16), which is necessary for subsequent p15 and p21 induction 1 . Mutation of Smad3 CDK phosphorylation sites also increased its ability to downregulate c-myc (Fig. 3d) . Downregulation of c-myc might involve an active repression mechanism, a possibility that requires further investigation.
The above observations prompted us to ask whether Smad3 can inhibit cell cycle progression from G1 to S phase, and whether mutation of the CDK phosphorylation sites renders it more effective in executing this function. Previous studies have shown that Smad3 together with Smad2 and Smad4 activates p15 expression, and introduction of Smad3 into Smad3 2/2 mouse embryonic fibroblasts (MEF) restores the p15 reporter gene induction by TGF-b (ref. 11). Smad3 2/2 primary MEF proliferated faster than the wildtype littermate MEF in the 3 H-thymidine incorporation assay, and the TGF-b growth-inhibitory effects were largely lost in the Smad3 2/2 primary MEF (Fig. 4a and ref. 21 ). To determine whether mutation of the CDK phosphorylation sites enables Smad3 to be more effective at inhibiting G1 cell cycle progression, we generated retroviral vectors that express either the wild-type Smad3 or the various CDK phosphorylation mutants of Smad3, and then used them to infect Smad3 2/2 primary MEF. As shown in Fig. 4b , wildtype Smad3 increased the cell population in G0/G1 phase and decreased the cell population in S phase. The various CDK phosphorylation mutants of Smad3 augmented these effects. Accordingly, these mutants were more effective than the wild-type Smad3 in inhibiting cell proliferation as measured by the 3 H-thymidine incorporation assay (Fig. 4c ) and cell number (Fig. 4d) , accompanied by increased p15 expression and lower c-Myc levels (Fig. 4e) . In addition to the Smad3 2/2 primary MEF, we have also observed the same trend in other cell types including the Mv1Lu epithelial cells, which contain relatively low levels of wild-type Smad3 (data not shown). Taken together, these observations indicate that phosphorylation of Smad3 by CDK facilitates cell cycle progression from G1 to S phase. Thus, we have shown that Smad3 is phosphorylated by CDK4 and CDK2. Mutation of its CDK phosphorylation sites increases its transcriptional activity and antiproliferative function. We propose that under physiological conditions, phosphorylation of Smad3 by CDK inhibits its transcriptional activity, contributing to a decreased level of p15 and an increased level of c-Myc, thus facilitating cell cycle progression from G1 to S phase. In the presence of physiological concentrations of TGF-b, normal cells are inhibited by TGF-b. However, cancer cells often contain high levels of CDK activities because of frequent amplification, translocation or overexpression of the cyclin D1 gene or inactivation of the tumour suppressor p16 (refs 5, 6) . In addition, overexpression of cyclin E and decreases in CDK inhibitor p27 levels also occur in cancer cells 26 . Inactivation of Smad3 and presumably the homologous Smad2 by extensive CDK phosphorylation may provide an important mechanism for resistance to the TGF-b growth-inhibitory effects in cancers.
A 
Phosphorylation in vitro by reconstituted CDK
GST-CDK4, GST-CDK2 and His-tagged cyclins D, E and A were expressed and purified from Escherichia coli as described previously 27 . GST-CDK and His-cyclin were mixed and incubated with HeLa extracts in the presence of ATP and Mg 2þ to activate CDK4 or CDK2. Cyclin D-CDK4 was reconstituted as described previously 28 except that no MnCl 2 was included. The cyclin D-CDK4 complex was then purified with glutathione agarose beads. Cyclin E-CDK2 and cyclin A-CDK2 were reconstituted as described previously 27 and purified by successive Ni-nitrilotriacetate-agarose and glutathione-agarose chromatography. The purified cyclin-CDK complexes were used to phosphorylate substrates for 40 min in 20 ml reactions containing 35 mM HEPES pH 7.4, 10 mM 
Phosphorylation in vivo
For analysis of endogenous Smad3 phosphorylation, Mv1Lu mink lung epithelial cells were synchronized at G0/G1 phase by contact inhibition in complete medium as previously described 23 . In brief, Mv1Lu cells were grown to full confluence in complete medium. Cells were then split and plated into fresh medium. At different time points, cells were phosphate-starved for 0.5 h and then labelled for 1.5 h with 1 mCi ml 21 32 P-orthophosphate. Cells were lysed in a buffer containing 10 mM Tris pH 7.8, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P40, and protease and phosphatase inhibitors, and immunoprecipitated by a Smad3-specific antibody. For analysis of transfected Flag-tagged Smad3 phosphorylation, Mv1Lu/L17 or COS cells were transfected by DEAE-dextran. At 30-36 h after transfection, cells were phosphate-starved for 45 min and labelled with 32 P-orthophosphate at 1 mCi ml 21 for 2.5 h followed by immunoprecipitation by a Flag antibody.
Retrovirus production
Wild-type or CDK phosphorylation mutant Smad3 were subcloned into the retroviral vector pLZRSD-IRES-GFP 29 and transfected into ecotropic phoenix packaging cells to produce retroviruses as described previously 30 .
Smad3
2/2 MEF were infected at greater than 90% efficiency.
Generation of MEF and 3 H-thymidine incorporation assay
Smad3 þ/2 mice were crossed and MEF were generated as described previously 21 ; 2 £ 10 5 Smad3 2/2 primary MEF and the wild-type littermate control MEF (both at passage 3) were seeded in six-well plates for 24 h, then treated for 24 h with or without 500 pM TGF-b. During the last 4 h, 5 mCi of 3 H-thymidine was added to the culture, and 3 H-thymidine incorporation was assayed as described previously 21 .
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